What's the most recent regulatory action in Chronic idiopathic thrombocytopenic purpura?

Most recent: Promacta — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-idiopathic-thrombocytopenic-purpura.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Chronic idiopathic thrombocytopenic purpura — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic idiopathic thrombocytopenic purpura (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic idiopathic thrombocytopenic purpura, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tavalisse	FOSTAMATINIB	Rigel Pharms		Receptor-type tyrosine-protein kinase FLT3	2018-01-01
Promacta	ELTROMBOPAG	Novartis	Thrombopoietin Receptor Agonist	Thrombopoietin receptor	2008-01-01
Nplate	ROMIPLOSTIM	Amgen	Thrombopoietin Receptor Agonist [EPC]	Thrombopoietin receptor	2008-01-01
Nplate	Nplate	Nantes University Hospital		Thrombopoietin receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-16 — Promacta · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Amgen · 1 drug in Chronic idiopathic thrombocytopenic purpura
Nantes University Hospital · 1 drug in Chronic idiopathic thrombocytopenic purpura
Novartis · 1 drug in Chronic idiopathic thrombocytopenic purpura
Rigel Pharms · 1 drug in Chronic idiopathic thrombocytopenic purpura

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic idiopathic thrombocytopenic purpura:

Cite this brief

Drug Landscape (2026). Chronic idiopathic thrombocytopenic purpura — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-idiopathic-thrombocytopenic-purpura. Accessed 2026-06-11.

Chronic idiopathic thrombocytopenic purpura full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing